SynthesisClinical and experimental nephrology2006
Meta-analysis of antiplatelet therapy for IgA nephropathy.
Synthesis in Clinical and experimental nephrology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Antiplatelet agents for chronic kidney disease.The Cochrane database of systematic reviews · 2022Pooled it
- Evidence-based practice guideline for the treatment of CKD.Clinical and experimental nephrology · 2009Guideline
- Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.Chinese medical journal · 2016Trial
- Pharmacological interventions in IgA nephropathy: protocol for a living systematic review and network meta-analysis.BMJ open · 2025Article
- Serum sCD40L and IL-31 in Association with Early Phase of IgA Nephropathy.Journal of clinical medicine · 2023Article
- Measuring and interpreting platelet-leukocyte aggregates.Platelets · 2018Review
- Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease.Oncotarget · 2018Article
- Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis.Scientific reports · 2017Article
- Use of off-label nephrology-related drugs in hospitalized pediatric patients: a retrospective study.World journal of pediatrics : WJP · 2016Article
- The Development of a Checklist to Enhance Methodological Quality in Intervention Programs.Frontiers in psychology · 2016Article
- Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease.The Kaohsiung journal of medical sciences · 2014Article
- Nationwide survey on current treatments for IgA nephropathy in Japan.Clinical and experimental nephrology · 2013Article
- Chapter 10: Immunoglobulin A nephropathy.Kidney international supplements · 2012Article
- Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Advances in chronic kidney disease · 2011Review
- The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease.Nature reviews. Nephrology · 2010Review
- Functional expression of IgA receptor FcalphaRI on human platelets.Journal of leukocyte biology · 2008Article
- Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.Clinical and experimental nephrology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiplatelet agents have been widely used in the management of immunoglobulin A (IgA) nephropathy in the Japanese population. To systematically evaluate the effects of antiplatelet agents for IgA nephropathy, we conducted a meta-analysis of the published studies.
methodsData sources consisted of MEDLINE, EMBASE, the Cochrane Library, Ityu-shi (Japanese medical database), and bibliographies from the studies. The quality of the studies was evaluated from the intention to treat analysis and allocation concealment, as well as by the Jadad method. Meta-analyses were performed on the outcomes of proteinuria and renal function.
resultsSeven articles met the predetermined inclusion criteria. The use of antiplatelet agents showed statistically significant effects on proteinuria and renal function. The pooled risk ratio for proteinuria was 0.61 (95% confidence intervals (CI) 0.39-0.94) and for renal function it was 0.74 (95% CI 0.63-0.87).
conclusionsAntiplatelet agents resulted in reduced proteinuria and protected renal function in patients with IgA nephropathy. However, studies of high-quality design were rare, and most studies assessed surrogate outcomes. More properly designed studies are needed to reach a definitive assessment of this matter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.